Advertisement

Indications and Outcome of PPM and ICD Placement

  • Joseph J. Germano
  • Joshua R. DeLeon
  • Daniel R. Zakhary
  • Mark E. Josephson
Chapter

Abstract

The use of synchronized atrioventricular (AV) pacing devices and implantable cardioverter-defibrillators (ICDs) plays a critical role in the management of hypertrophic cardiomyopathy (HCM). Indications for pacing and defibrillators follow the standard guidelines for treatment of conduction disease and arrhythmias in the general population, with distinct additional indications for HCM patients based on the potential to mitigate diastolic dysfunction and outflow tract gradients, and the potential for life-threatening ventricular arrhythmia and sudden cardiac death. ICDs can be a life-saving therapy in high-risk HCM patients, but the early placement of these devices in younger patients may expose them to a higher lifetime risk of complications. Given the unique nature of HCM, specific procedural and programming considerations should be taken into account.

Keywords

Hypertrophic cardiomyopathy Pacemaker Implantable-cardioverter defibrillator Device programming Sudden cardiac death Appropriate implantable-cardioverter defibrillator Inappropriate implantable-cardioverter defibrillator 

References

  1. 1.
    Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90:2731–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet. 1992;339:1318–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29:435–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Slade AK, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75:44–9.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Posma JL, Blanksma PK, Van Der Wall EE, Vaalburg W, Crijns HJ, Lie KI. Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy. Heart. 1996;76:358–62.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation. 1998;98:242–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Yue-Cheng H, Zuo-Cheng L, Xi-Ming L, et al. Long-term follow-up impact of dual-chamber pacing on patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2013;36:86–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J. 1997;18:1249–56.PubMedCrossRefGoogle Scholar
  10. 10.
    Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99:2927–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Qintar M, Morad A, Alhawasli H, et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database Syst Rev. 2012;5:CD008523.Google Scholar
  12. 12.
    Gao YC, Li Y, Han ZH, Zhang XL, Zhao H, Jiang TY. Transcoronary ablation of septal hypertrophy versus dual-chamber cardiac pacing for the treatment of aged patients with hypertrophic obstructive cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:333–6.PubMedGoogle Scholar
  13. 13.
    Mickelsen S, Bathina M, Hsu P, Holmes J, Kusumoto FM. Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function. J Interv Card Electrophysiol. 2004;11:47–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Silva LA, Fernandez EA, Martinelli Filho M, et al. Cardiac pacing in hypertrophic cardiomyopathy: a cohort with 24 years of follow-up. Arq Bras Cardiol. 2008;91(250–6):74–80.Google Scholar
  15. 15.
    Berruezo A, Vatasescu R, Mont L, et al. Biventricular pacing in hypertrophic obstructive cardiomyopathy: a pilot study. Heart Rhythm. 2011;8:221–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Knyshov G, Lazoryshynets V, Rudenko K, et al. Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy? Interact Cardiovasc Thorac Surg. 2013;16:5–9.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Galve E, Sambola A, Saldana G, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart. 2010;96:352–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Cannon 3rd RO, Tripodi D, Dilsizian V, Panza JA, Fananapazir L. Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 1994;73:571–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408.PubMedCrossRefGoogle Scholar
  20. 20.
    Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365–73.PubMedCrossRefGoogle Scholar
  22. 22.
    Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405–12.PubMedGoogle Scholar
  23. 23.
    Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1–8.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Maron BJ, Maron MS, Lesser JR, et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol. 2008;101:544–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol. 2004;44:398–405.PubMedCrossRefGoogle Scholar
  26. 26.
    Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–20.PubMedGoogle Scholar
  27. 27.
    O’Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98:116–25.PubMedCrossRefGoogle Scholar
  28. 28.
    Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence – strategies to prevent sudden death. Fundam Clin Pharmacol. 2010;24:637–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol. 2006;97:1255–61.PubMedCrossRefGoogle Scholar
  30. 30.
    Maron BJ, Haas TS, Shannon KM, Almquist AK, Hodges JS. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm. 2009;6:993–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Maron BJ, Spirito P, Ackerman MJ, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61:1527–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Gadler F, Linde C, Juhlin-Dannfeldt A, Ribeiro A, Ryden L. Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1996;27:1219–24.PubMedCrossRefGoogle Scholar
  33. 33.
    Lenarczyk R, Wozniak A, Kowalski O, et al. Effect of cardiac resynchronization on gradient reduction in patients with obstructive hypertrophic cardiomyopathy: preliminary study. Pacing Clin Electrophysiol. 2011;34:1544–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Roberts BD, Hood RE, Saba MM, Dickfeld TM, Saliaris AP, Shorofsky SR. Defibrillation threshold testing in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2010;33:1342–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail. 2012;5:552–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Syska P, Przybylski A, Chojnowska L, et al. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol. 2010;21:883–9.PubMedGoogle Scholar
  37. 37.
    Lin G, Nishimura RA, Gersh BJ, et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart. 2009;95:709–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Lawrence D, Von Bergen N, Law IH, et al. Inappropriate ICD discharges in single-chamber versus dual-chamber devices in the pediatric and young adult population. J Cardiovasc Electrophysiol. 2009;20:287–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol. 2011;58:1007–13.PubMedCrossRefGoogle Scholar
  40. 40.
    Peterson PN, Varosy PD, Heidenreich PA, et al. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA. 2013;309:2025–34.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Almendral J, Arribas F, Wolpert C, et al. Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial. Europace. 2008;10:528–35.PubMedCrossRefGoogle Scholar
  42. 42.
    Theuns DA, Klootwijk AP, Goedhart DM, Jordaens LJ. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. J Am Coll Cardiol. 2004;44:2362–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Deisenhofer I, Kolb C, Ndrepepa G, et al. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc Electrophysiol. 2001;12:134–42.PubMedCrossRefGoogle Scholar
  44. 44.
    Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation. 2006;113:2871–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2012;9:1737–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Hauser RG, Maron BJ, Marine JE, et al. Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. Heart Rhythm. 2008;5:1517–22.PubMedCrossRefGoogle Scholar
  47. 47.
    Woo A, Monakier D, Harris L, et al. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart. 2007;93:1044–5.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009;2:474–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509–13.PubMedCrossRefGoogle Scholar
  51. 51.
    Silva JN, VON Bergen NH, Dubin AM, et al. Assessment of intrathoracic impedance algorithm in the pediatric and adult congenital population. Pacing Clin Electrophysiol. 2014;37:1174–1180Google Scholar
  52. 52.
    Nishimura RA, Hayes DL, Ilstrup DM, Holmes Jr DR, Tajik AJ. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol. 1996;27:421–30.PubMedCrossRefGoogle Scholar
  53. 53.
    Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52:541–50.PubMedCrossRefGoogle Scholar
  54. 54.
    Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006;48:330–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110:2591–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Cha YM, Gersh BJ, Maron BJ, et al. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2007;18:483–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRefGoogle Scholar
  58. 58.
    Maisel WH. Pacemaker and ICD generator reliability: meta-analysis of device registries. JAMA. 2006;295:1929–34.PubMedCrossRefGoogle Scholar
  59. 59.
    Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm. 2007;4:892–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Maisel WH. Transvenous implantable cardioverter-defibrillator leads: the weakest link. Circulation. 2007;115:2461–3.PubMedCrossRefGoogle Scholar
  61. 61.
    Maisel WH. Semper fidelis–consumer protection for patients with implanted medical devices. N Engl J Med. 2008;358:985–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115:2474–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  • Joseph J. Germano
    • 1
  • Joshua R. DeLeon
    • 1
  • Daniel R. Zakhary
    • 1
  • Mark E. Josephson
    • 2
    • 3
    • 4
  1. 1.Department of Medicine and Division of CardiologyStony Brook Medical School, Winthrop-University HospitalMineolaUSA
  2. 2.Department of Medicine and Division of CardiologyBeth Israel Deaconess Medical CenterBostonUSA
  3. 3.Department of Medicine and Division of CardiologyHarvard-Thorndike Electrophysiology Institute and Arrhythmia Service, Beth Israel Deaconess Medical CenterBostonUSA
  4. 4.Harvard Medical SchoolBostonUSA

Personalised recommendations